None of the rechallenged mice developed new tumors, in contrast with 100% of naive mice receiving similar s.c. injections, suggesting a potent anti-tumor immune memory provided by the combination treatment against both CT26 KRASG12C+/+ and CT26 WT tumor cells (Fig. 3F). This evidence concerns the gene DDX53 and neoplasm.